Signs of PCOS and Fatty Liver: How Insulin Resistance Affects Both and What to Do About It

Eight hours of sleep and you are still exhausted. Your periods come irregularly, or sometimes not at all. Your skin breaks out the way it did when you were seventeen, and however carefully you eat, weight settles around your belly and refuses to move. Somewhere down the Google spiral, two terms keep surfacing together: PCOS and fatty liver disease.

Here is what may surprise you: the two conditions are deeply connected, and the thread joining them is a metabolic problem called insulin resistance. Understanding that link is not merely academically interesting. It can change how you approach your own health entirely.

What is PCOS, really?

Polycystic ovary syndrome affects an estimated 8–13% of women of reproductive age worldwide, making it the most common endocrine disorder in that group.¹ Despite the name, cysts on the ovaries are not actually required for diagnosis. The Rotterdam criteria — the most widely used framework — require at least two of three features: irregular or absent ovulation; elevated androgen levels, or symptoms of them such as excess hair growth and acne; and polycystic ovarian morphology on ultrasound.²

What those criteria fail to capture is quite how metabolic PCOS really is. For decades it was classified primarily as a reproductive disorder. The science now tells a different story.

The insulin resistance connection

At the centre of PCOS — in 65–80% of affected women — sits insulin resistance.³ The body's cells stop responding normally to insulin, the hormone that signals them to take up glucose from the blood. The pancreas compensates by producing more and more of it, and insulin levels stay chronically elevated: hyperinsulinemia.

For the ovaries this has a very specific consequence. Insulin directly stimulates the theca cells of the ovary to produce androgens — male sex hormones such as testosterone.⁴ In a woman with insulin resistance, the ovaries are effectively receiving a constant signal to overproduce testosterone. Disrupted ovulation, irregular periods, acne and hirsutism follow. This is not a hormone problem that happens to affect metabolism; it is a metabolic problem that derails hormones.

Insulin resistance in PCOS is driven partly by intrinsic defects in insulin signalling at the cellular level. Research has identified a post-receptor signalling defect unique to women with PCOS: excessive serine phosphorylation of the insulin receptor substrate, which impairs glucose uptake even in women of normal weight.⁵ Insulin resistance in PCOS, in other words, is not always about excess body fat. It is built into the biology of the condition.

Enter the liver

This is where it gets genuinely interesting. The liver is one of the primary tissues responding to insulin. Under insulin resistance it loses the ability to regulate fat metabolism properly. Rather than packaging and exporting fat efficiently, it accumulates fat within its own cells — non-alcoholic fatty liver disease (NAFLD), now more accurately termed metabolic dysfunction-associated steatotic liver disease (MASLD).⁶

Women with PCOS show significantly higher NAFLD prevalence than women without it, even after controlling for body mass index. A 2016 meta-analysis by Qu and colleagues found PCOS associated with a two-fold increased risk of NAFLD.⁷ A more recent systematic review confirmed that the elevated risk holds across ethnicities and body weight categories — meaning lean women with PCOS remain at elevated risk.⁸

What drives fat into the liver in PCOS? Several mechanisms:

• Hyperinsulinemia directly stimulates de novo lipogenesis — the liver manufacturing new fat from glucose.⁹

• Elevated androgens promote visceral fat accumulation, which releases free fatty acids straight into the portal circulation feeding the liver.¹⁰

• Dysbiosis of the gut microbiome, increasingly documented in PCOS, contributes to increased intestinal permeability and liver inflammation.¹¹

Recognising the signs: when both are present

The difficulty with fatty liver disease is that it stays largely silent in its early stages — most people simply do not feel it. But where PCOS and fatty liver coexist, certain patterns are worth recognising.

Signs that may indicate PCOS

• Irregular menstrual cycles — fewer than 8 cycles per year, or cycles longer than 35 days

• Hirsutism — excess hair growth on face, chin, chest or abdomen

• Acne — particularly along the jawline and chin, the classic androgen-driven distribution

• Thinning scalp hair (androgenic alopecia)

• Acanthosis nigricans — velvety, darkened skin in body folds such as the neck and armpits, a hallmark of insulin resistance

• Difficulty losing weight, especially around the abdomen

• Fatigue and brain fog, particularly after carbohydrate-heavy meals

• Mood disturbances — rates of anxiety and depression are significantly higher in women with PCOS¹²

Signs that may indicate fatty liver

• Upper right abdominal discomfort or heaviness — where the liver sits, though not everyone experiences it

• Persistent fatigue that rest does not improve

• Elevated liver enzymes (ALT and AST) on blood work — though enzymes can be normal even with fatty liver

• Elevated triglycerides and low HDL cholesterol

• Elevated fasting insulin, or a HOMA-IR score above 2.5

• Unexplained weight gain, or difficulty losing weight

• Bloating and digestive discomfort

There is substantial overlap between the two lists — which makes sense, since they share a root cause.

The vicious cycle

What makes this metabolic pairing so insidious is that each condition worsens the other. Fatty liver produces and releases pro-inflammatory cytokines, TNF-α and IL-6 among them, which further impair insulin signalling in peripheral tissues.¹³ More inflammation, more insulin resistance, more androgen production, more visceral fat, more liver fat. A self-reinforcing loop.

A landmark study in the Journal of Clinical Endocrinology & Metabolism showed that women with both PCOS and NAFLD had significantly worse insulin sensitivity and higher androgen levels than women with PCOS alone — suggesting that liver involvement amplifies the endocrine disruption of PCOS.¹⁴

Unaddressed, fatty liver in PCOS can progress. MASLD runs along a spectrum: simple steatosis (fat accumulation), then metabolic steatohepatitis (MASH, formerly NASH, with inflammation and liver cell damage), then fibrosis, then cirrhosis. Studies suggest women with PCOS are more likely to have the advanced inflammatory form, MASH, rather than simple fat accumulation.¹⁵

What the science says about treatment

The good news is that insulin resistance — the shared root of both conditions — is genuinely modifiable. Here is what carries the strongest evidence.

1. Lifestyle modification: the non-negotiable foundation

Modest weight loss of 5–10% of body weight, in women with PCOS who are overweight, significantly improves menstrual regularity, reduces androgen levels and improves insulin sensitivity.¹⁶ In NAFLD, similar weight loss — above 7% particularly — has been shown to reduce hepatic fat content substantially, and can even reverse early fibrosis.¹⁷

Diet quality matters more than macronutrient ratios. A 2019 randomised controlled trial found a low-GI diet improved menstrual cyclicity and reduced markers of insulin resistance in PCOS more effectively than a conventional healthy diet.¹⁸ For liver health, the Mediterranean dietary pattern has the most robust evidence: it reduces hepatic fat, improves insulin sensitivity and lowers cardiovascular risk.¹⁹

Dietary strategies with evidence behind them:

• Reduce ultra-processed foods and added sugars — fructose in particular drives de novo lipogenesis in the liver.²⁰

• Increase fibre intake from vegetables, legumes and whole grains — fibre feeds the beneficial gut bacteria that produce short-chain fatty acids, which improve insulin sensitivity.

• Prioritise anti-inflammatory fats — omega-3 fatty acids from oily fish reduce hepatic triglycerides and inflammation.²¹

• Time-restricted eating — emerging evidence suggests it improves insulin sensitivity and reduces hepatic fat, though long-term RCT data specific to PCOS remain limited.²²

Exercise is independently powerful. Both aerobic and resistance training improve insulin sensitivity through mechanisms that bypass the insulin receptor defect seen in PCOS: muscle contraction activates GLUT4 transporters via an insulin-independent pathway.²³ Which means that even with deregulated insulin signalling, exercise may override the problem. A meta-analysis of exercise interventions in PCOS found both training types reduced fasting insulin and HOMA-IR.²⁴

2. Inositol supplementation

Myo-inositol and D-chiro-inositol are naturally occurring compounds involved in insulin signalling, and among the most promising supplements for PCOS. A 2019 systematic review found myo-inositol improved ovulation rates, reduced androgen levels and improved insulin sensitivity in women with PCOS, with a favourable safety profile.²⁵

For liver health specifically, inositol plays a role in lipid metabolism, and animal studies suggest benefits for hepatic steatosis — though human RCT data on liver outcomes in PCOS specifically remain limited.²⁶

3. Metformin

Metformin, an insulin sensitiser widely used in type 2 diabetes, has decades of track record in PCOS. It reduces insulin levels, modestly reduces androgen production and can restore menstrual regularity.²⁷ It also activates AMPK (AMP-activated protein kinase) in the liver, a key enzyme promoting fat oxidation and inhibiting fat synthesis — which may explain its modest but real benefit in NAFLD.²⁸

4. Optimising gut health

Emerging research is sharpening the focus on the gut-liver axis. Dysbiosis in PCOS increases intestinal permeability ("leaky gut"), letting bacterial products such as lipopolysaccharide (LPS) reach the liver via the portal vein and trigger inflammation.¹¹ Probiotic supplementation has produced promising early results: a 12-week RCT found Lactobacillus-based probiotics improved insulin resistance and reduced inflammatory markers in women with PCOS.²⁹

5. Addressing sleep

Chronically underrated. Sleep disruption — including obstructive sleep apnoea, which is disproportionately common in PCOS — independently worsens insulin resistance and promotes liver fat accumulation.³⁰ If you are doing everything right and still seeing no results, a sleep study may be worth discussing with your doctor.

What to ask your doctor

If you have PCOS, ask about:

• Baseline liver function tests (ALT, AST, GGT) and hepatic ultrasound, to screen for fatty liver.

• Fasting insulin and HOMA-IR — not just fasting glucose. Glucose can read normal for years while insulin runs high, before blood sugar finally tips over.

• Lipid panel — triglycerides and HDL are particularly relevant.

• HbA1c, to assess average blood sugar over three months.

• Referral to a dietitian experienced in PCOS and metabolic health.

If fatty liver is found, ask whether you should be referred to a hepatologist and what the degree of steatosis is. Knowing your baseline gives you something to measure improvement against.

The bottom line

PCOS and fatty liver disease are not two separate problems that happen to coincide. They are largely two faces of the same underlying metabolic dysfunction. Insulin resistance sits at the centre of both, driving hormonal chaos in the ovaries while quietly loading fat into the liver.

The encouraging truth is that treating the root — improving insulin sensitivity through evidence-based lifestyle change, targeted supplementation and, where appropriate, medication — benefits both conditions at once. You do not need two treatment plans. You need one coherent strategy aimed at the metabolic core.

That is not a small thing. It is genuinely empowering.

References

Cited by the original article:

1. Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855. PMID: 27664216

2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. PMID: 14711538

3. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030. PMID: 23065822

4. Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83(6):2001–2005. PMID: 9626130

5. Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. J Clin Invest. 1995;96(2):801–810. PMID: 7635975

6. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. PMID: 37363821

7. Qu Z, Zhu Y. Association between polycystic ovary syndrome and non-alcoholic fatty liver disease: a meta-analysis. Exp Ther Med. 2016;12(4):2500–2506. PMID: 27698750

8. Deng Y, Liu Z, Wang L, et al. Non-alcoholic fatty liver disease in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2021;43(1):151–159. PMID: 33896716

9. Lim JS, Mietus-Snyder M, Valente A, et al. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010;7(5):251–264. PMID: 20368739

10. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG. 2006;113(10):1148–1159. PMID: 16827826

11. Torres PJ, Siakowska M, Banaszewska B, et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab. 2018;103(4):1502–1511. PMID: 29340590

12. Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32(5):1075–1091. PMID: 28333286

13. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008;14(3–4):222–231. PMID: 18235842

14. Tan S, Bechmann LP, Benson S, et al. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab. 2010;95(1):343–348. PMID: 19906812

15. Brzozowska MM, Ostapowicz G, Weltman M. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol. 2009;24(2):243–247. PMID: 19054265

16. Lim SS, Hutchison SK, Van Ryswyk E, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;3:CD007506. PMID: 30921465

17. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378. PMID: 25865049

18. Marsh KA, Steinbeck KS, Atkinson FS, et al. Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome. Am J Clin Nutr. 2010;92(1):83–92. PMID: 20484445

19. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–846. PMID: 28545937

20. Stanhope KL. Sugar consumption, metabolic disease and obesity: the state of the controversy. Crit Rev Clin Lab Sci. 2016;53(1):52–67. PMID: 26376619

21. Scorletti E, Bhatia L, McCormick KG, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME study. Hepatology. 2014;60(4):1211–1221. PMID: 25043514

22. Cienfuegos S, Gabel K, Kalam F, et al. Effects of 4- and 6-h time-restricted feeding on weight and cardiometabolic health. Cell Metab. 2020;32(3):366–378. PMID: 32813017; and Xie W, Liao Q, Chen Y, et al. Eight-hour time-restricted feeding improves endocrine and metabolic profiles in women with anovulatory polycystic ovary syndrome. J Clin Endocrinol Metab. 2021;106(3):e1355–e1366. PMID: 33170263

23. Holloszy JO. Regulation by exercise of skeletal muscle content of mitochondria and GLUT4. J Physiol Pharmacol. 2008;59(Suppl 7):5–18. PMID: 19258654

24. Patten RK, Boyle RA, Moholdt T, et al. Exercise interventions in polycystic ovary syndrome: a systematic review and meta-analysis. Front Physiol. 2020;11:606. PMID: 32760280

25. Pundir J, Psaroudakis D, Savnur P, et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2018;125(3):299–308. PMID: 28544572

26. Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95(10):1811–1827. PMID: 23850516

27. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592. PMID: 24151290

28. Pernicova I, Korbonits M. Metformin — mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–156. PMID: 24393785

29. Ahmadi S, Jamilian M, Karamali M, et al. Probiotic supplementation and the effects on weight loss, glycaemia and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Hum Fertil (Camb). 2017;20(4):254–261. PMID: 28427289

30. Theorell-Haglöw J, Berne C, Janson C, et al. Obstructive sleep apnoea is associated with decreased insulin sensitivity in females. Eur Respir J. 2008;31(5):1054–1060. PMID: 18184682